Emami Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8oarsg229celtigtyc12vywf.pdf

Key Takeaways


Demand & Volume Trends

Mohan Goenka: "We are very confident that the markets should improve today or tomorrow. In fact, let me also share that we are happy to see the numbers coming in the last 10, 15 days, post all the holiday season. So there is some buoyancy coming in, in the wholesale markets, particularly for the winter products and it is across the board."

Margins & Cost Structure

Mohan Goenka: "We are committed to invest behind our brands and also to invest behind the distribution channels. Also, we see very healthy growth coming in from the Healthcare channels. So we have a lot of investments to do going forward. And so margins should be in the pre-COVID levels around 27%. If natural margin expansion happens, it happens. Otherwise, you should expect around 27% margins."

Brand & Portfolio Health

Mohan Goenka: "Our aspirations may not be so high, Abneesh. It has come as a range. But we don't want to dilute our margins. That is very, very clear."

Channel & Distribution


International Business

Vivek Dhir: "Macroeconomic is not in our hands, but our actions to overcome those issues are in our hands. So we are working around that area so that these markets also continue to perform for this."

Guidance & Commitments

CommitmentSpecificsTimeline
Core EBITDA margin~27% (pre-COVID level), excluding HeliosFY23 full year
Helios margin impactMax 0.2%-0.3% depletion on reported marginsH2 FY23
Gross margin pressureNot much pressure expected as input cost inflation moderatesH2 FY23
Input cost pressureNo margin pressures expectedQ3 FY23
BoroPlus growthDouble-digit growthFY23 full year
International growth~12-14% growthQ3 FY23
GCC manufacturing localisationReach maximum localisation objectivesBy end FY23
Rural distribution footprintReach 50,000 villages; then add ~10,000 villages/yearBy year-end; next 2 years
NPD contributionRamp to ~3% of salesGoing forward
MAT credit utilisationTax rate below 10% for FY23, ~10% for next yearFY23; FY24
Kesh King amortisationRun rate of ₹45-50 crore/quarter to continueNext few quarters
Dermicool, Creme 21 amortisation~₹23.5 crore/quarter to continueFor some time
Healthcare performanceBetter overall performance vs last yearFrom next quarter onwards

Key Metrics

MetricQ2 FY23
Net sales₹807 cr, +4% YoY
Revenue₹814 cr, +3% YoY
Domestic business growth+1.2% YoY, volume degrowth of 1.2%
Domestic business 3-year CAGR8%
Core domestic business growth+5% YoY, excluding pain management, healthcare range, and Helios Lifestyle
Gross margin66.6%, contracted 230 bps YoY
A&P spendincreased 400 bps YoY
EBITDA₹195 cr, declined 29% YoY
Profit before tax₹186 cr, declined 18% YoY
Profit after tax₹180 cr, declined 3% YoY
H1 FY23 EBITDA margin23.2%, lower by 760 bps YoY
Full-year EBITDA margin guidance (core business)~27%, pre-COVID levels
International business growth+17% YoY
Modern Trade growth+28% YoY
E-commerce growth+56% YoY
Modern Trade + E-commerce share of domestic revenue16.5%, up from 11.3% in Q2 FY22
BoroPlus range growth+17% YoY
Kesh King range growth-10% YoY, 3-year CAGR of 14%
Pain Management range growth-13% YoY
Healthcare range growth-16% YoY
Helios Lifestyle (The Man Company) contribution to net sales3.5%
Zanducare online run rate~₹2 cr per month
NPD contribution to sales~1–1.5%, expected to ramp to ~3%
Rural distribution footprint42,000 villages, target 50,000 by year-end
Effective tax rate guidance (FY23)below 10%, due to MAT credit utilization